What 6 Analyst Ratings Have To Say About NeoGenomics

In the latest quarter, 6 analysts provided ratings for NeoGenomics NEO, showcasing a mix of bullish and bearish perspectives.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for NeoGenomics, revealing an average target of $20.67, a high estimate of $24.00, and a low estimate of $19.00. Observing a 0.34% increase, the current average has risen from the previous average price target of $20.60.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive NeoGenomics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NeoGenomics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NeoGenomics compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of NeoGenomics's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of NeoGenomics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know NeoGenomics Better

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Unraveling the Financial Story of NeoGenomics

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: NeoGenomics's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 12.15%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -9.21%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NeoGenomics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.52% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): NeoGenomics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.85%, the company may face hurdles in achieving optimal financial returns.

Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.65, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Understanding the Relevance of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.